Quick Facts
Plain-English Summary
Thymosin Alpha-1 (Tα1) is an endogenous peptide that the human body produces naturally in the thymus gland. It was first characterised by Allan Goldstein and colleagues at George Washington University in the 1970s as a biologically active component of thymosin fraction 5, a thymic extract studied for its immune-restorative properties. Unlike many compounds in the longevity and peptide research space, Tα1 is not a synthetic construct — the pharmaceutical form is structurally identical to the molecule produced endogenously, with N-terminal acetylation preserved as a requirement for full biological activity.
The compound has one of the most extensive clinical evidence bases of any peptide in off-label research use. It is an approved pharmaceutical drug — marketed as Zadaxin by SciClone Pharmaceuticals — in approximately 35 countries, including China, Italy, the Philippines, and several other Asian and Eastern European nations. Approved indications across these jurisdictions include chronic hepatitis B, chronic hepatitis C (typically in combination with interferon), and as an adjunct in cancer immunotherapy. Randomised controlled trials have demonstrated meaningful improvements in hepatitis B surface antigen seroconversion rates and virological response compared to interferon monotherapy.
The absence of FDA or EMA approval is largely a commercial and regulatory filing matter rather than a primary safety concern. SciClone Pharmaceuticals chose not to pursue the lengthy and costly FDA approval process for the North American market, and the compound's patent landscape made commercial investment in a new drug application less attractive. This regulatory gap has created a situation where a well-characterised, globally approved drug circulates in North America primarily through compounding pharmacies and the research peptide market.
Unlike most research peptides, Thymosin Alpha-1 has completed multiple randomised controlled trials in human populations and holds pharmaceutical approval in dozens of countries. Its clinical profile is substantially better-documented than the majority of compounds in this category.
The COVID-19 pandemic generated additional interest in Tα1. Chinese clinical trials conducted between 2020 and 2022 investigated its use in severely ill hospitalised patients with COVID-19, reporting reduced 28-day mortality compared to standard care. These findings are preliminary and have not been replicated in large international multi-centre trials; they should be interpreted cautiously, not as definitive evidence of efficacy. The biological rationale — restoration of T-cell function in immunocompromised critically ill patients — is coherent with the compound's established mechanism, but extrapolation beyond the specific trial contexts is premature.
Quality is a critical variable for this compound. Biological activity depends entirely on preservation of the N-terminal acetylation; degraded or improperly manufactured Tα1 loses its immunomodulatory activity. This makes sourcing and third-party verification particularly important for any research application.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Murine immunodeficiency | Restored T-cell populations and functional immune responses in thymectomised mice. Foundational studies establishing the compound's biological role as a thymic hormone. Goldstein AL et al. 1972 ↗ | Preclinical |
| Murine tumour models | Significant tumour growth reduction and survival extension in syngeneic tumour-bearing mice when used as adjunct to chemotherapy. Attributed to NK cell and CTL enhancement. Garaci E et al. 1994 ↗ | Preclinical |
| Aged murine immune senescence | Partial restoration of T-cell function and cytokine production in aged mice, supporting the longevity research hypothesis. Effects on thymic output in ageing models replicated across multiple groups. | Preclinical |
| Viral infection models (influenza, LCMV) | Reduced viral titres and improved survival in murine viral infection models. Enhanced IFN-γ and IL-2 production quantified. Underpins rationale for antiviral clinical trials. | Preclinical |
| Murine sepsis / immunosuppression | Reduced mortality in cecal ligation and puncture (CLP) sepsis model. Immune reconstitution observed in post-chemotherapy immunosuppressed animals — biological basis for critically ill COVID-19 trial rationale. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| RCT — Chronic Hepatitis B | Multicentre; Tα1 1.6 mg SC twice weekly vs. interferon-α vs. combination; 6–12 months | — | Positive RCT |
| Phase III — Chronic Hepatitis C (Italy) | Tα1 + interferon vs. interferon alone; n=97; 12 months | — | Positive RCT |
| Non-small cell lung cancer adjunct (China) | Tα1 + chemotherapy vs. chemotherapy alone; multiple trials; 1990s–2010s | — | Moderate Evidence |
| COVID-19 severe illness (China, 2020–2022) | Tα1 in hospitalised severe COVID-19 patients with lymphopenia; n=229 (largest trial); RCT design | — | Preliminary |
| All COVID-19 findings — international replication | — | — | Awaiting Replication |
Thymosin Alpha-1 has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
In multiple Phase II and Phase III clinical trials across hepatitis B, hepatitis C, and oncology indications, Thymosin Alpha-1 has demonstrated a favourable tolerability profile. No dose-limiting toxicity was identified in trials up to 6.4 mg SC per dose. Adverse event rates in Tα1 arms were generally comparable to or lower than interferon monotherapy comparators.
Biological activity is entirely dependent on intact N-terminal acetylation. Improperly synthesised or degraded Tα1 is not merely less effective — it may be biologically inert. This creates a meaningful quality risk in compounded and research-grade preparations, where acetylation integrity is not routinely verified by purchasers.
- Mild injection site reactions (redness, transient swelling)
- Fatigue during initial days of use — may reflect immune activation
- Low-grade flu-like symptoms in some users at initiation
- No serious adverse events reported in off-label community use at standard doses
- Short half-life (~2 hours SC) limits systemic accumulation
- Active autoimmune disease (theoretical immune amplification risk)
- Post-transplant on immunosuppression
- Active or suspected malignancy without oncology oversight
- Pregnancy or breastfeeding (no safety data)
- Concurrent biological or immunomodulatory therapy
Thymosin Alpha-1 is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Thymosin Alpha-1 for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
What I find most interesting about Tα1 compared to the other longevity peptides is that it's one of the few with actual RCT data in humans that wasn't generated by the company selling it. The hepatitis B trial data from the 90s is genuinely independent. That matters. Yes, the hepatitis B indication doesn't map directly onto the immune ageing use case — but it validates the immunomodulatory mechanism in a population with documented immune dysfunction, which at least gives you something real to anchor the broader hypothesis to. Most of the other peptides in this space can't say that.
Fair point on the hepatitis data. The extrapolation question is still open though — immunocompromised HBV patients are a different population from healthy adults using this for longevity reasons. Whether Tα1 meaningfully restores T-cell repertoire breadth in already immunocompetent, middle-aged people is just not something we have data on. The animal immunosenescence studies are suggestive but not quantitatively useful for predicting an effect size in humans.
The acetylation point is underappreciated by most people buying this. It's not just about purity — it's about the specific chemical modification that determines whether the molecule actually binds. I've seen people buy "thymosin alpha-1" that hasn't been verified for N-terminal acetylation and assume it's the same compound. It isn't. The market incentives around this aren't great: acetylation verification adds cost and complexity. Most vendors don't confirm it. HPLC purity is necessary but not sufficient to confirm biological activity for this particular peptide.
Worth separating two things the community often conflates: (1) Tα1 as an adjunct in documented immune dysfunction or active disease — hepatitis, cancer, sepsis — where there's RCT-level support, and (2) Tα1 as prophylactic immune "optimisation" in healthy individuals, for which there is no controlled data at all. The first is backed by reasonable evidence. The second is plausible mechanistically but genuinely unevaluated. Most of the people actually using this fall into category two, and most of the evidence people cite comes from category one.
This is an honest and accurate summary of the evidence gap. The longevity use case is essentially running ahead of the science — which is common in this space — but Tα1 at least has the advantage of a well-characterised safety profile and approved pharmaceutical precedent. That's a better starting position than most.
One thing that helps contextualise the FDA situation: SciClone is primarily a China-focused pharmaceutical company. Their business model was never built around US market penetration for Zadaxin. The lack of FDA approval isn't a signal of a failed NDA — there was no NDA because there was no commercial rationale to file one. That's genuinely different from compounds that tried and failed to get approval. The compound itself passed regulatory review in over 30 countries. That's meaningful context that gets lost when people see "not FDA approved" and assume the worst.